Our Product Pipeline
Rubix’s clinical-stage pipeline is based on synthetic regenerative compound molecules for the treatment of targeted regions with strong potential to evolve the intersection of implantable combination devices. Studies suggest that these compounds may facilitate physical interactions between synthetic and organic receptors that result in enhanced activity, offering new potential for a variety of diseases with unmet needs.
Indication: MS, PLS & ALS
Quantum Digital Therapeutic Informatics companion tool
Indication: Glioma tumors (Primary target: DIPG; Secondary: GBM)